Overview of Dr. Maris
Michael Maris, MD, is a board-certified, fellowship-trained medical oncologist who focuses on the treatment of myeloid and lymphoid diseases. Dr. Maris has decades of experience treating these types of blood cancers through innovative therapies, especially blood and marrow transplantation. He believes in shared decision making, partnering with his patients by providing clear information about the disease and treatment options, empowering them to make the best decisions for their own care plans.
Dr. Maris earned his undergraduate degree at West Virginia University and went on to complete his medical degree at the University of Pennsylvania. He then completed an internal medicine residency at the Oregon Health Sciences University in Portland, OR followed by an oncology and blood and marrow transplantation fellowship at the Fred Hutchinson Cancer Research Center/University of Washington in Seattle, WA. Dr. Maris' fellowship research focus was expanding the role of allogeneic transplantation to older and infirm patients through the use of non-myeloablative allogeneic hematopoietic stem cell transplantation and he has published extensively in this area.
Dr. Maris' current research interests are in further optimizing allogeneic hematopoietic transplantation for patients of all types as well as the development of novel drug and drug regimens for the treatment of the patients with acute myeloid leukemia. Dr. Maris has extensive experience as an investigator in multiple clinical trials and Dr. Maris has expertise in the treatment of patients with acute myeloid leukemia.
In his free time, Dr. Maris enjoys spending time with his family as well as hiking, skiing, running, biking, and travel.
Office
1800 Williams St
Ste 300
Denver, CO 80218Fax+1 720-754-4801
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 1998 - 2001
- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1995 - 1998
- Perelman School of Medicine at the University of PennsylvaniaClass of 1995
Certifications & Licensure
- OR State Medical License 1997 - Present
- CO State Medical License 2005 - 2025
- WY State Medical License 2009 - 2025
- NM State Medical License 2013 - 2017
- WA State Medical License 1998 - 2006
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib Start of enrollment: 2001 Jul 13
- Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
- Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor Start of enrollment: 2004 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 77 citationsPhase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromesGuillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G. Berdeja, Yasmin Abaza, Elias J. Jabbour
Cancer. 2017-03-15 - 201 citationsAllogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphomaMichael B. Maris, Brenda M. Sandmaier, Barry E. Storer, Thomas R. Chauncey, Monic J. Stuart
Blood. 2004-12-01 - 140 citationsRelapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningChristoph Kahl, Barry E. Storer, Brenda M. Sandmaier, Marco Mielcarek, Michael B. Maris
Blood. 2007-10-01
Abstracts/Posters
- Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled StudyMichael B. Maris, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell ...Michael B. Maris, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...Michael B. Maris, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Grant Support
- Nonmyeloablative Allografting For Hematologic NeoplasiaNational Cancer Institute2001–2005
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem PPO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
First Health PPOGreat West PPO
Humana ChoiceCare Network PPO
Kaiser Permanente
Multiplan PHCS PPO
Multiplan PPO
Rocky Mountain Group/Indiv - HMO/Private Pay
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: